

Click on the link below to be directed to study information at "ClinicalTrials.Gov" the US National Institutes of Health website.

Condition		Active Research Studies	St. Luke's Contact
<u>ANATOMICAL SITE</u>	<u>RESEARCH BASE & REFERENCE #</u>	<u>STUDY TITLE</u>	<u>ST. LUKE'S CONTACT</u>
<u>MDS</u>	NHLBI-MDS NCT02775383	The National Myelodysplastic Syndromes Natural History Study	Karley, 218-249-5002 whiteside@slhduluth.com
<u>BREAST</u>	Alliance A011202 NCT01901094	A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy	Karley, 218-249-5002 whiteside@slhduluth.com
<u>BREAST</u>	NRG-BR002 NCT02364557	A Phase IIR/III Trial of Standard of Care Therapy With or Without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer	Karley, 218-249-5002 whiteside@slhduluth.com
<u>BREAST</u>	iCaRe ²	Integrated Cancer Repository for Cancer Research	Allison, 218-249-5902 whiteside@slhduluth.com
<u>LUNG Small Cell Lung Cancer</u>	NRG-CC003 NCT02635009	Randomized Phase II/III Trial of Prophylactic Cranial Irradiation With or Without Hippocampal Avoidance for Small Cell Lung Cancer	Karley, 218-249-5002 whiteside@slhduluth.com
<u>LUNG NSCLC</u>	NRG-LU002 NCT03137771	Maintenance Systemic Chemotherapy Versus Consolidative Stereotactic Body Radiation Therapy (SBRT) Plus Maintenance Chemotherapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III Trial	Karley, 218-249-5002 whiteside@slhduluth.com
<u>LUNG NSCLC</u>	Alliance A151216 NCT02194738	Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)	Karley, 218-249-5002 whiteside@slhduluth.com
<u>NSCLC</u>	Alliance A081105 NCT02193282	Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)	Karley, 218-249-5002 whiteside@slhduluth.com
<u>NSCLC</u>	CTSU E4512 NCT02201992	A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein	Karley, 218-249-5002 whiteside@slhduluth.com

<u>BLADDER</u>	SWOG S1605 NCT02844816	<u>Phase II Trial of Atezolizumab in BCG-Unresponsive Non-muscle Invasive Bladder Cancer</u>	Katie, RN, 218-249-5337 <u>whiteside@slhduluth.com</u>
<u>PROSTATE</u> Intermediate- Risk, High-Risk	RTOG 0924 NCT01368588	<u>Androgen Deprivation Therapy and High Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial</u>	Karley, 218-249-5002 <u>whiteside@slhduluth.com</u>
<u>COLORECTAL</u>	AbbVie M14-064 NCT03368859	<u>Phase 2 Study Comparing Efficacy and Safety of ABT-165 Plus FOLFIRI vs Bevacizumab Plus FOLFIRI in Metastatic Colorectal Cancer Previously Treated With Fluoropyrimidine/Oxaliplatin and Bevacizumab</u>	Efrem RN, 218-249-5581 <u>whiteside@slhduluth.com</u>
<u>RECTAL</u>	NRG-GI002 NCT02921256	<u>A Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal Cancer</u>	Karley, 218-249-5002 <u>whiteside@slhduluth.com</u>